Advancing Cancer Therapy: A Review of Recent Progress in Monoclonal Antibodies
Buddadasari Snehitha
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.
Mopuri Jyothsna
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.
Akula Ruchitha Sai
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.
Binaya Sapkota
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.
Bandaru Revanth
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.
K Somasekhar Reddy
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.
Bhupalam Pradeep Kumar *
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.
*Author to whom correspondence should be addressed.
Abstract
A new era in cancer treatment has begun with the development of monoclonal antibodies (mAbs), which have improved therapeutic results and precision targeting to a great extent. Specialized monoclonal antibodies (mAbs) are engineered to attach specifically to cancer antigens, allowing them to directly target tumor cells and influence the immune system for therapeutic purposes. Significant advancements in this field include the approval and clinical efficacy of mAbs that target B-cell lymphomas and HER2-positive breast cancer. Notable cases like as trastuzumab and rituximab highlight the real benefits of these treatments, which include better patient outcomes and survival rates.
Furthermore, by triggering the body's immunological defenses against cancer cells, immune checkpoint inhibitors like pembrolizumab have completely changed the way that cancer is treated. For individuals with previously difficult-to-treat illnesses, this innovative technique has shown extraordinary success across a variety of cancer types.
Innovative approaches including antibody-drug conjugates and bispecific antibodies have also been produced by ongoing developments in mAb engineering. These technical miracles improve the overall safety profile of monoclonal antibodies (mAb) therapeutics by compensating for off-target effects and optimizing therapeutic efficacy. There are still issues, such as toxicity and the emergence of drug resistance, in spite of significant progress. Even Nevertheless, continued research and development initiatives highlight the enormous potential of monoclonal antibodies in customized cancer treatment plans. These advances promise a better future for cancer patients everywhere by highlighting the quick evolution of cancer therapies and encouraging increased research and innovation in this vital area of medicine.
Keywords: Immunotherapies, Her2-positive breast cancer, targeted antigens, oncology, Car T Cell treatment